This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
Welcome to Reed Smith's viewpoints — timely commentary from our lawyers on topics relevant to your business and wider industry. Browse to see the latest news and subscribe to receive updates on topics that matter to you, directly to your mailbox.
| 1 minute read

A Cannabis Bill is (re)born

Friends, it’s happened again. The lesser-known “Marijuana 1-to-3 Act of 2019”, first submitted by House Rep. Greg Steube (R-Fla.) in September 2019 (bill is here; reported here) has been submitted once again by Rep. Steube as the “Marijuana 1-to-3 Act of 2021”, as reported by Law360. (link) The only thing that appears to have changed about the proposal law is the date in the title.

What would this proposed law do? True to its name, it would reschedule non-hemp cannabis to a Schedule III controlled substance, akin to codeine and ketamine (link). The law would not only open up testing and research, but it would also meant that IRS Code 280E would no longer apply (since 280E only applies to trafficking in Schedule I and II controlled substances - link).

What’s the likelihood of this going anywhere? Ish vis nisht! (link). I personally still think that we’re more likely to see a comprehensive legalization and regulatory scheme (link; indeed, I’m not the only one to speculate that the cannabis industry may soon be fighting alcohol, tobacco, and other companies in the political arena: (link)), but the reintroduction of this bill in these early days of the 2021 Congress is a curious curveball as the policy debates begin in earnest.


cannabis, schedule 1, schedule iii

Latest Insights